Oct 3, 2019
At ESMO 2019, Samsung Bioepis reveals positive results from Phase 3 study comparing its SB8 with Avastin in patients with metastatic or recurrent NSCLC.
A Phase 3 study comparing Samsung Bioepis’ SB8 with Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR).